Blood Pressure Medication Recall: Everything You Need To Know

Aurobindo Pharma USA, Inc. has recalled 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets USP and Valsartan Tablets USP. The blood pressure medication was detected to have trace levels of N-nitrosodiethylamine (NDEA) which could cause cancer.

According to the company, NDEA has been classified as a probable carcinogen by the International Agency for Research on Cancer. NDEA is naturally found in certain foods, drinking water, air pollution, and industrial processes. A full list of recalled medication can be found here.

The recalled blood pressure medication is used to control high blood pressure and the treatment of heart failure. Patients taking the affected medication should continue taking the tablets as prescribed as the risk of stopping the medication without an alternative treatment is higher. Consumers should contact their pharmacist or physician about starting an alternative medical treatment.

It is also suggested that consumers contact their healthcare provider if they experience any issues with the medication. The company has not received any reports of adverse effects from the recalled blood pressure medication.

Consumers who have questions about the recall or those who want to report an adverse effect of the recalled medication can contact Aurobindo Pharma USA at: 1-866-850-2876. Questions about returning the medication can be directed to Inmar/CLS-Medturn at 1-877-208-2407 from 9 am. To 5 p.m. EST or by email at rxrecalls@inmar.com.

Adverse reactions or quality issues can also be reported to the FDA’s MedWatch Event Reporting program. Call 1-800-332-1088 or submit a report online at www.fda.gov/medwatch/report.htm. Forms can be mailed or faxed (1-800-FDA-0178) by first downloading them from www.fda.gov/MedWatch/getforms.htm.